Observational studyBMC cancer2026
Real-world trends in diagnosis, treatment, and survival of non-small cell lung cancer in Vietnam.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vietnamese expert consensus on the diagnosis and multidisciplinary management of resectable non-small cell lung cancer.Translational lung cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence describing temporal changes in disease stage, molecular testing, treatment patterns, and survival outcomes in non-small cell lung cancer (NSCLC) from low- and middle-income countries remains scarce. We assessed longitudinal real-world trends in NSCLC management and outcomes at a provincial oncology center in Vietnam over more than six years.
methodsThis retrospective observational study included consecutive adults with histologically confirmed NSCLC treated at Nghe An Oncology Hospital, Vietnam between January 2018 and August 2024 (n = 3,087). Trends in stage at diagnosis (AJCC 8th edition), biomarker testing uptake (primarily epidermal growth factor receptor [EGFR]; limited anaplastic lymphoma kinase [ALK]), and first-line treatment modalities were evaluated. Overall survival (OS) was estimated using the Kaplan-Meier method and compared across diagnosis periods using log-rank tests. Multivariable Cox proportional hazards models were used to identify independent prognostic factors.
resultsThe median age was 64 years (range, 24-97), 73.5% were male, 71.6% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adenocarcinoma accounted for 77.0% of cases. The proportion of early-stage disease (stage I-II) increased from 3.1% in 2018 to 9.8% in 2023-2024, while stage III disease declined from 33.3% to 20.4%. Molecular testing uptake increased from 28.7% to a peak of 65.1% in 2022 and remained approximately 60% thereafter. Use of first-line targeted therapy rose from 7.7% to 20.8%, and immunotherapy from 0% to 2.5%. Median OS improved from 12.0 months in 2018 to 21.7 months in 2023-2024 (log-rank p < 0.001). Diagnosis during 2021-2024 was independently associated with lower mortality compared with 2018-2020 (adjusted HR 0.80, 95% CI 0.73-0.87).
conclusionsSubstantial improvements in diagnosis, molecular testing, and treatment adoption were observed over time and were associated with significantly improved survival in a large real-world Vietnamese NSCLC cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.